First charges come in generic price-fixing probe

Accusations levied against former Heritage execs are part of a sweeping investigation by the DOJ into the pricing and marketing of generic drugs in the U.S. 

By Ned Pagliarulo • Dec. 14, 2016

Sanofi, Celgene flagged for misleading DTC ads

Television commercials for Sanofi's Toujeo and Celgene's Otezla both ran afoul of the FDA for creating misleading impressions on safety. 

By Ned Pagliarulo • Dec. 14, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

Xcertia launched to improve mobile health apps

The new nonprofit will promote best practices, aiming to draw in stakeholders from across industry and academia.

By Suzanne Elvidge • Dec. 14, 2016

CVS Health unveils diabetes cost-control program

Several months after rival Express Scripts rolled out spending caps for diabetes drugs, CVS will offer cost savings to patients who improve control of their disease. 

By Lisa LaMotta • Dec. 14, 2016

Bristol-Myers hit with marketing fine for Abilify

Off-label promotion of the antidepressant landed the biopharma in hot water with the NY Attorney General. 

By Suzanne Elvidge • Dec. 12, 2016

Endo chops sales force after ditching pain drug

The Irish biopharma plans to pump the resources saved from the decision into its branded drug portfolio.

By Jacob Bell • Dec. 8, 2016

Pfizer hit with record fine in UK for drug price hike

A U.K. competition regulator fined Pfizer and Flynn Pharma about $113 million for sharply increasing the price of an epilepsy drug by as much as 2600%. 

By Ned Pagliarulo • Dec. 7, 2016

Report: Biosimilars, specialty drugs inversely impact drug spend

While specialty drugs can be pricey and are slated to take up a bigger chunk of drug spending, biosimilars could curb the amount stakeholders pay for some drugs.

By Jacob Bell • Dec. 7, 2016

Novo Nordisk becomes latest pharma to criticize pricing system

The Danish drugmaker blames a complicated pricing system in the U.S. that hurts profits and doesn't celebrate innovation. 

By Lisa LaMotta • Dec. 7, 2016

QuintilesIMS projects slower drug spending growth through 2021

The annual report cited loss of patent exclusivity and greater rebate use as reasons for the slower growth.

By Jacob Bell • Dec. 5, 2016

Eli Lilly, Boehringer secure CV label for Jardiance

The FDA gave the companies an early Christmas present, approving an expanded indication for the diabetes drug which Lilly hopes will be a catalyst for sales. 

By Ned Pagliarulo • Dec. 2, 2016

Biofrontera expands US marketing for skin drug

The German biotech company is expanding its sales force as it commercializes its drug for actinic keratosis in the U.S.

By Judy Packer-Tursman • Nov. 30, 2016

Novo Nordisk pulls ad from Breitbart

The Danish biopharma joins Kellogg, Allstate and the San Diego Zoo, among others, in yanking ads from the website.

By Jacob Bell • Nov. 30, 2016

Valeant grows Salix sales team as deal rumors swirl

The beleaguered specialty pharma is growing the sales force for Xifaxan and Relistor, as new speculation surfaces about a potential sale of Salix.  

By Suzanne Elvidge • Nov. 30, 2016

Novartis donates $10M in generics to global relief

This donation is the latest iteration of the big pharma's long-standing collaboration with Americares.

By Judy Packer-Tursman • Nov. 23, 2016

Walgreens expands partnership providing patient drug reviews

The deal will provide more detailed product reviews from online forum PatientLikeMe's more than 400,000 users.

By Jacob Bell • Nov. 22, 2016

Novo, Sanofi get same-day approval for diabetes drug combos

The FDA's approvals put both companies on equal footing as they continue to struggle for a competitive advantage. 

By Jacob Bell • Nov. 22, 2016

Uncertainty reigns at Alexion

The spec pharma has put investors on edge after being opaque about potential problems with Soliris marketing practices. 

By Lisa LaMotta • Nov. 16, 2016

FDA issues warning to Supernus for 'misleading' marketing

The agency took aim at a recent video for Oxtellar RX, a product responsible for a quarter of the company's revenue.

By Jacob Bell • Nov. 16, 2016

Boxed warning added to label of Bayer's Essure

The FDA decided to require the warning in February, but solicited comments from the industry and other stakeholders on its approach. 

By Ned Pagliarulo • Nov. 16, 2016

Novartis builds social media community for heart failure patients

"Together in HF," a social network two years in the making, has attracted 500 members so far. 

By Judy Packer-Tursman • Nov. 16, 2016

Amid pricing criticism, Ariad builds patient outreach

The company debuted new engagement efforts to support its work in ALK+ lung cancer. But scrutiny over pricing practices might leave more of a mark. 

By Suzanne Elvidge • Nov. 16, 2016

Lilly touts Jardiance heart benefit ahead of FDA decision

Seeking a competitive edge, Eli Lilly presented new findings weeks before the FDA decides on labeling.

By Judy Packer-Tursman • Nov. 15, 2016

Costs for many Medicare drugs continue steady rise

The undiscounted cost of 11 drugs more than doubled last year, led by Valeant's treatment for high blood sugar, Glumetza. 

By Ned Pagliarulo • Nov. 15, 2016

Orexigen and Valeant bulk up Contrave deal

The two floundering companies expanded a marketing partnership into new territories. 

By Lisa LaMotta • Nov. 9, 2016